摩根士丹利下调英普瑞医疗目标价至182美元 较此前预期缩水9%

华尔街洞察
15 Jul

摩根士丹利最新研报将Inspire Medical Systems(股票代码:INSP)的目标股价从每股200美元调降至182美元,降幅达9%。此次调整后,该目标价较当前市价仍存在约15%的潜在上行空间。

此次分析师评级变动发生在美东时间7月15日上午交易时段,正值医疗器械板块经历波动行情。专业机构指出,呼吸机疗法领域竞争加剧及二季度患者就诊量季节性波动,或是触发估值模型调整的关键因素。

目标价修正通常反映机构对标的公司短期增长动能与行业前景的重新评估。值得注意的是,此次调整后摩根士丹利仍维持对该股的"增持"评级,暗示其长期基本面未发生本质变化。市场参与者正密切关注将于下月发布的Q2财报,以验证该公司的现金流转化能力是否匹配当前估值水平。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10